Abstract

Radioresistance represents a major obstacle in cancer treatment, the underlying mechanism of which is complex and not well understood. miR-148b has been reported to be implicated regulating radioresistance in lymphoma cells. However, this function has not been investigated in lung cancer cells. Microarray analysis was performed in A549 cells 48h after exposure to 8 Gy of γ-irradiation or sham irradiation to identify differentially expressed miRNAs. miR-148b mimic and inhibitor were transfected, followed by clonogenic survival assay to examine response to irradiation in A549 cells. Western Blot and luciferase assay were performed to investigate the direct target of miR-148b Xenograft mouse models were used to examine invivo function of miR-148b Our data showed that expression of miR-148b was significantly down-regulated in both serum and cancerous tissues of radioresistant lung cancer patients compared with radiosensitive patients. Overexpression of miR-148b reversed radioresistance in A549 cells. MutL homologue 1 (MLH1) is the direct target of miR-148b which is required for the regulatory role of miR-148b in radioresistance. miR-148b mimic sensitized A549 xenografts to irradiation invivo Our study demonstrated that miR-148b regulates radioresistance of lung cancer cells by modulating MLH1 expression level. miR-148b may represent a new therapeutic target for the intervention of lung cancer.

Highlights

  • Lung cancer is one of the leading causes of cancer-related deaths worldwide [1]

  • MiR-148b expression is negatively related to radioresistance in lung cancer In order to identify the miRNAs implicated in lung cancer radiosensitivity, miRNA sequencing was used to monitor their expression in A549 cells 48 h after radiation treatment

  • The difference in this expression was statistically significant before and after irradiation in A549 cells (P = 0.0003) as confirmed by quantitative real-time PCR (Supplementary Figure S1B). miR-148b expression was analysed in lung cancerous tissues and matched non-cancerous tissues as well as serum from 20 CRC patients

Read more

Summary

Introduction

Non-small cell lung cancer (NSCLC) represents the most common type of lung cancer and accounts for approximately 80 % of all lung cancer cases [2,3]. The 5-year overall survival rate of NSCLC cases is lower than 15 % [3,4]. 40 % of NSCLC patients have unresectable stage III disease or medically inoperable disease [5]. Radiotherapy has been regarded as one of the main treatment strategies for NSCLC. It is generally thought to be due to tumour heterogeneity related to cell of origins, pathology, aetiology and molecular/genetic pathogenesis [8], the underlying mechanism remains unclear. There is an urgent need to develop novel approaches for the intervention of NSCLC, such as targeted gene treatment as a radiosensitizer

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call